Since HER2 expression is associated with radioresistance in breast cancer [4, 16], siRNA-mediated silencing of HER2 was employed to test whether HER2 is the key mediator of radioresistance in HER2-positive breast cancer cells. The gene discussed is ERBB2; the disease is breast carcinoma.